Livongo Reports Fourth Quarter and Full Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Livongo Health (LVGO) Tops Q4 EPS by 7c, Revenues Beat; Offers Q1 & FY20 Revenue Guidance Above Consensus
March 2, 2020 4:18 PM ESTLivongo Health (NASDAQ: LVGO) reported Q4 EPS of $0.02, $0.07 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $50.2 million versus the consensus estimate of $49.27 million.
Fourth Quarter 2019 Highlights:
ASC 606:
Revenue: Total revenue for the quarter was $50.4 million, up 137% year-over-year. Gross Margin: GAAP gross margin of 78.3% and non-GAAP gross margin of 79.2%, which reflects continued scaling in the delivery of our offerings and includes an adjustment related to capitalization of device costs for certain solutions. Net Loss: GAAP net loss of $6.0 million, and net loss per share... More